FibroGen logo
FibroGen
FGEN | NASDAQ
Chart Builder DCF Calculator
$9.07
-$0.15 (-1.63%)
At close: Jan 12, 2026, 09:30 AM ET

FibroGen Company Profile

Company profile explained

Company Profile

FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases. This drug has successfully completed Phase III clinical trials in the US, Europe, China, and Japan for treating anemia in chronic kidney disease, and is currently in Phase II/III development in China for anemia linked to myelodysplastic syndromes. Additionally, the company is progressing Pamrevlumab, a human monoclonal antibody designed to block connective tissue growth factor. Pamrevlumab is undergoing Phase III clinical development for multiple conditions including idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, with a separate Phase III trial also underway for Duchenne muscular dystrophy. FibroGen maintains strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. Established in 1993, FibroGen, Inc. operates from its headquarters in San Francisco, California.

Key Executives

Name Position
Thane Wettig Chief Executive Officer & Director
David DeLucia Senior Vice President & Chief Financial Officer
Gaia Vasiliver-Shamis Director of IR & Communications - LifeSci Advisors
John Alden Corporate Secretary & General Counsel

Latest SEC Filings

Date Type Title
Oct 01, 2026 8-K Current Report
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Aug 31, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 10-Q Quarterly Report
Aug 13, 2026 8-K Current Report
Jun 17, 2026 4 Filing
Jun 17, 2026 4 Filing
Jun 17, 2026 4 Filing
View All SEC Filings ➞
FibroGen
FibroGen logo
Country United States
IPO Date Nov 14, 2014
Industry Biotechnology
Sector Healthcare
Employees 225
CEO Thane Wettig

Contact Details

409 Illinois Street San Francisco, California 94158 United States

Stock Details

Ticker Symbol FGEN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000921299
CUSIP Number 31572Q881
ISIN Number US31572Q8814
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.